CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $818,000, lower than 95% of all stocks globally
- PositionOperating margin is -32248.7%, lower than 95% of its Biotechnology peers (median -45.9%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
604.76MUSDvs all stocks (USD)
Revenue (TTM)
818.00KUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.80xvs all stocks
52-Week Change
-51.13%vs all stocks
Market Capitalization
604.76MUSDvs all stocks (USD)
Enterprise Value
1.21BUSDvs all stocks (USD)
Forward P/E
-2.52xvs Biotechnology peers
Enterprise to Revenue
1.48Kxvs Biotechnology peers
Enterprise to EBITDA
-7.12xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-35.66%vs Biotechnology peers
Revenue (TTM)
818.00KUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0050USDUpdated Oct 28, 2026Quarterly Revenue Growth
-32.10%vs Biotechnology peers
Gross Profit (TTM)
818.00KUSDvs all stocks (USD)
EBITDA (TTM)
-170.37MUSDvs all stocks (USD)
Net Income (TTM)
-84.16MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-32.13%vs Biotechnology peers
Operating Cash Flow (TTM)
-141.17MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-83.84MUSDvs all stocks (USD)
Minority Interest (Equity)
1.31BUSDFY2025 · Dec 31, 2025Revenue
893.00KUSDFY2025 · Dec 31, 2025Operating Income
-165.01MUSDvs all stocks (USD)
Pre-tax Income
-151.20MUSDFY2025 · Dec 31, 2025Income Tax Expense
414.00KUSDFY2025 · Dec 31, 2025Net Income
-151.61MUSDFY2025 · Dec 31, 2025EBIT
-151.19MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-144.62MUSDFY2025 · Dec 31, 2025Research & Development
114.12MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
51.78MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.81MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
4.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.5200USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.5200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
133.94MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
133.94MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-151.61MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
82.63MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-124.33MUSDFY2025 · Dec 31, 2025Free Cash Flow
-139.53MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
108.54MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-151.61MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
6.58MUSDFY2025 · Dec 31, 2025Stock-based Compensation
25.34MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-29.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.32MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-5.92MUSDFY2025 · Dec 31, 2025Capital Expenditures
-15.20MUSDFY2025 · Dec 31, 2025Purchase of Investments
-217.08MUSDFY2025 · Dec 31, 2025Sale of Investments
318.02MUSDFY2025 · Dec 31, 2025Other Investing Activity
18.21MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
103.97MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-26.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
24.22MUSDFY2025 · Dec 31, 2025Shares Outstanding
205.72MSharesUpdated Oct 28, 2026Float Shares
184.65MSharesUpdated Oct 28, 2026Shares Short
23.79MSharesUpdated Oct 28, 2026Short Ratio
14.27daysvs all stocks
Short % of Shares Outstanding
15.31%vs all stocks
% Held by Insiders
46.45%vs all stocks
% Held by Institutions
26.51%vs all stocks
Total Cash (MRQ)
181.56MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.8690USDUpdated Oct 28, 2026Total Debt (MRQ)
3.52MUSDvs all stocks (USD)
Current Ratio (MRQ)
8.36xvs Biotechnology peers
Book Value per Share (MRQ)
-4.29USDUpdated Oct 28, 2026Total Assets
335.57MUSDvs all stocks (USD)
Total Current Assets
280.68MUSDFY2025 · Dec 31, 2025Total Liabilities
34.78MUSDFY2025 · Dec 31, 2025Total Non-current Assets
54.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
30.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
108.54MUSDFY2025 · Dec 31, 2025Other Short-term Investments
161.48MUSDFY2025 · Dec 31, 2025Accounts Payable
940.00KUSDFY2025 · Dec 31, 2025Short-term Debt
1.07MUSDFY2025 · Dec 31, 2025Long-term Debt
2.96MUSDFY2025 · Dec 31, 2025Common Stock (Book)
30.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.27BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
300.79MUSDvs all stocks (USD)
52-Week Low
1.30USDUpdated Oct 28, 202652-Week High
3.27USDUpdated Oct 28, 202652-Week Change
-51.13%vs all stocks
Beta
1.80xvs all stocks
50-Day MA
1.66USDUpdated Oct 28, 2026200-Day MA
1.84USDUpdated Oct 28, 2026Avg 10-Day Volume
990.35KSharesUpdated Oct 28, 2026Avg 30-Day Volume
1.46MSharesUpdated Oct 28, 2026Diluted EPS (TTM)
-0.5300USDUpdated Oct 28, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -32248.7%, lower than 95% of its Biotechnology peers (median -45.9%)Significant
Operating margin: -322.487Industry median: -0.46Industry P5: -46.61Peers compared: 255
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.51
Altman Z-Score 4.54: safe zoneNotable
Altman Z-Score: 4.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $818,000, lower than 95% of all stocks globallySignificant
Revenue (USD): 818,000Global P5: 36,021,613.518
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhongzhu Healthcare Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Hansen Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nuvectis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
4D Molecular Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zevra Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jinling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Candel Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shengda Resources Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Chongqing Sansheng Industrial Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Guangdong Jinma Entertainment Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown